Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial

Medicine & Life Sciences

• Adrenal Cortex Hormones 6%
• Asthma 46%
• Child 25%
• Eosinophils 8%
• Guidelines 16%
• Health Care Outcome Assessment 5%
• Hispanic Americans 8%
• Injections 4%
• Intention 15%
• Intention to Treat Analysis 9%
• mepolizumab 100%
• Morbidity 5%
• Mortality 4%
• National Institute of Allergy and Infectious Diseases (U.S.) 13%
• Nose 6%
• Phenotype 10%
• Placebos 41%
• Population 10%
• Random Allocation 16%
• Research Personnel 11%
• Safety 4%
• Therapeutics 6%
• Vulnerable Populations 8%